share_log

浙江圣达生物药业股份有限公司2023年度向特定对象发行A股股票募集资金使用的可行性分析报告(修订稿)

Feasibility analysis report on the use of capital raised by Zhejiang Shengda Biopharmaceutical Co., Ltd. by issuing A-shares to specific targets in 2023 (revised draft)

Sensex a share ·  Feb 27
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more